◆

Subtypes

4

Plasmodium falciparum malaria MONDO:0005920

Malaria caused by Plasmodium falciparum with highest risk of severe disease and cerebral complications.

Show evidence (1 reference)

PMID:37924827 SUPPORT Human Clinical

"Plasmodium falciparum strains partly resistant to artemisinins are entrenched in the Greater Mekong region and have emerged in Africa, while Anopheles mosquito vectors continue to evolve physiological and behavioural resistance to insecticides."

Confirms falciparum malaria as a major clinical subtype with distinct resistance and transmission pressures.

Plasmodium vivax malaria MONDO:0005921

Malaria caused by Plasmodium vivax, notable for relapse biology driven by dormant liver hypnozoites.

Show evidence (1 reference)

PMID:37748496 SUPPORT Human Clinical

"Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear."

Establishes P. vivax as a subtype with hypnozoite biology requiring radical cure.

Cerebral malaria MONDO:0005625

Severe neurologic malaria syndrome characterized by brain microvascular pathology, coma, and seizures.

Show evidence (1 reference)

DOI:10.1186/s12987-024-00541-9 SUPPORT In Vitro

"Blood–brain barrier (BBB) disruption is a central feature of cerebral malaria (CM), a severe complication of Plasmodium falciparum (Pf) infections."

Supports cerebral malaria as a distinct severe subtype with BBB-focused pathogenesis.

Recurrent vivax malaria MONDO:0005921

Recurrent disease episodes due to relapse from persistent liver hypnozoites after initial infection.

Show evidence (1 reference)

PMID:37748496 SUPPORT Human Clinical

"At day 180, the risk of recurrence was 51·0% (95% CI 48·2-53·9) in 1470 patients treated without primaquine, 19·3% (16·9-21·9) in 2569 patients treated with a low total dose of primaquine (approximately 3·5 mg/kg), and 8·1% (7·0-9·4) in 2811 patients treated with a high total dose of primaquine..."

Demonstrates substantial recurrence burden in vivax malaria and links recurrence to hypnozoite-targeted therapy.

⚙

Pathophysiology

6

Infected erythrocyte sequestration and cytoadherence

In severe falciparum malaria, parasitized erythrocytes sequester in the microvasculature, promoting endothelial injury, impaired perfusion, and downstream organ dysfunction.

erythrocyte link endothelial cell link

cell adhesion link

blood link

Show evidence (1 reference)

PMID:27939609 SUPPORT Human Clinical

"Infected erythrocyte sequestration in the microvasculature plays a critical role in the development of severe disease"

Directly supports sequestration as a central severe-malaria mechanism.

Blood-brain barrier dysfunction in cerebral malaria

Cerebral malaria involves endothelial barrier breakdown with increased permeability and stress responses, linking vascular pathology to severe neurologic phenotypes.

endothelial cell link

inflammatory response link

brain link

Show evidence (2 references)

DOI:10.1186/s12987-024-00541-9 SUPPORT In Vitro

"Blood–brain barrier (BBB) disruption is a central feature of cerebral malaria (CM), a severe complication of Plasmodium falciparum (Pf) infections."

Establishes BBB disruption as a core pathophysiologic feature of cerebral malaria.

DOI:10.1186/s12987-024-00541-9 SUPPORT In Vitro

"After 6-h of co-culture with Pf-iRBCs, hiPSC-BMECs showed reduced TEER and increased sodium fluorescein permeability compared to co-culture with uninfected RBCs, indicative of a leaky barrier."

Demonstrates mechanistic endothelial barrier failure in an in vitro CM model.

EPCR-associated endothelial pathology

Parasite interactions with endothelial protein C receptor (EPCR) are associated with severe disease and suggest a pathway for enhanced vascular injury and dysregulated coagulation-inflammatory signaling.

endothelial cell link

inflammatory response link

Show evidence (1 reference)

PMID:27939609 SUPPORT Human Clinical

"The recent discovery that parasite binding to endothelial protein C receptor (EPCR) is associated with severe disease has suggested new mechanisms of pathology and provided new avenues for severe malaria adjunctive therapy research."

Supports EPCR-linked endothelial pathology as a severity mechanism.

Cerebrovascular CD8-positive T-cell engagement

Pediatric cerebral malaria includes intravascular and perivascular CD8-positive T-cell engagement at the cerebrovasculature, supporting an immune-mediated component of neurologic injury.

T cell link

inflammatory response link

brain link

Show evidence (2 references)

PMID:31821175 SUPPORT Human Clinical

"We identified effector CD3+CD8+ T cells engaged on the cerebrovasculature in 69% of CM+ HIV- children."

Provides direct human tissue evidence for cerebrovascular CD8-positive T-cell involvement.

PMID:31821175 SUPPORT Human Clinical

"Within the studied cohort, CM is associated with cerebrovascular engagement of CD3+CD8+ T cells, which is exacerbated by HIV coinfection."

Confirms association between cerebral malaria and cerebrovascular CD8-positive T-cell activity.

ABO-dependent rosetting and severe malaria risk

Host ABO genotype modifies falciparum rosetting behavior and contributes to differential risk of severe malaria.

erythrocyte link

cell adhesion link

blood link

Show evidence (2 references)

PMID:37708213 SUPPORT Human Clinical

"Blood group O is associated with protection against severe malaria and reduced size and stability of P. falciparum-host red blood cell (RBC) rosettes compared to non-O blood groups."

Supports RBC rosetting and host blood-group dependence in severe malaria risk.

PMID:37708213 SUPPORT Human Clinical

"In the case-control study, compared to OO, the double dose genotypes consistently had higher odds ratios (OR) for severe malaria than single dose genotypes, with AB (OR 1.93) and AO (OR 1.27) showing most marked difference (p = 0.02, Wald test)."

Restricts this evidence item to human case-control findings on genotype-specific severe-malaria risk.

Hypnozoite persistence and vivax relapse

Dormant P. vivax hypnozoites in the liver sustain recurrent malaria episodes unless eradicated with radical cure.

liver link

Show evidence (1 reference)

PMID:37748496 SUPPORT Human Clinical

"Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear."

Directly links dormant hypnozoites to the need for radical cure in recurrent vivax malaria.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

Referential integrity issues (1):

Target 'Recurrent vivax malaria' (from 'Hypnozoite persistence and vivax relapse') not found in named elements

●

Phenotypes

10

Blood 2

Anemia FREQUENT Anemia (HP:0001903)

Show evidence (1 reference)

PMID:8644955 SUPPORT Human Clinical

"There were no deaths, and complications were limited to thrombocytopenia and anemia."

Clinical complications in falciparum malaria include anemia.

Thrombocytopenia FREQUENT Thrombocytopenia (HP:0001873)

Show evidence (1 reference)

PMID:8644955 SUPPORT Human Clinical

"There were no deaths, and complications were limited to thrombocytopenia and anemia."

Directly supports thrombocytopenia as a clinical complication.

Cardiovascular 1

Splenomegaly OCCASIONAL Splenomegaly (HP:0001744)

Show evidence (1 reference)

PMID:25889074 SUPPORT Human Clinical

"Fever, tachycardia, pallor and abdominal pain on palpation were more frequent in P. falciparum patients, whereas mild hepatomegaly and splenomegaly were mostly observed with P. vivax."

Large Colombian clinical surveillance cohort documents splenomegaly, especially in vivax infection.

Digestive 1

Vomiting FREQUENT Vomiting (HP:0002013)

Show evidence (1 reference)

PMID:8644955 SUPPORT Human Clinical

"The most common documented symptoms were fever (100%), chills (65%), vomiting (60%), anorexia (45%), and headache (45%)."

Case-series symptom profile supports vomiting as a frequent manifestation.

Metabolism 1

Fever VERY_FREQUENT Fever (HP:0001945)

Show evidence (1 reference)

PMID:8644955 SUPPORT Human Clinical

"The most common documented symptoms were fever (100%), chills (65%), vomiting (60%), anorexia (45%), and headache (45%)."

Clinical case-series data show fever as the most frequent presenting feature.

Nervous System 3

Headache FREQUENT Headache (HP:0002315)

Show evidence (1 reference)

PMID:8644955 SUPPORT Human Clinical

"The most common documented symptoms were fever (100%), chills (65%), vomiting (60%), anorexia (45%), and headache (45%)."

Reported headache prevalence supports inclusion as a common malaria phenotype.

Coma OCCASIONAL Coma (HP:0001259)

Show evidence (1 reference)

PMID:40701686 SUPPORT Human Clinical

"The disease is defined clinically as an otherwise unexplained coma in someone with malaria parasitemia."

Human clinical neurology review defines coma as the core phenotype of cerebral malaria.

Seizure OCCASIONAL Seizure (HP:0001250)

Show evidence (1 reference)

PMID:40701686 SUPPORT Human Clinical

"Acute seizures are common and increasing numbers of them during the index illness are associated with a greater likelihood of adverse outcomes."

Human clinical evidence supports seizures as common, prognostically relevant cerebral-malaria manifestations.

Constitutional 2

Chills FREQUENT Chills (HP:0025143)

Show evidence (1 reference)

PMID:8644955 SUPPORT Human Clinical

"The most common documented symptoms were fever (100%), chills (65%), vomiting (60%), anorexia (45%), and headache (45%)."

Clinical series directly reports chills as a frequent presenting symptom.

Myalgia FREQUENT Myalgia (HP:0003326)

Show evidence (1 reference)

PMID:17568940 SUPPORT Human Clinical

"Headache (59.8%), fever (57.1%), and myalgia (48.4%) were the most frequent symptoms."

Prospective cohort data identifies myalgia among the most frequent malaria symptoms.

🧬

Genetic Associations

7

HBB (HbS trait) (Protective)

Show evidence (2 references)

PMID:22445352 SUPPORT Human Clinical

"Meta-analysis of case-control studies showed a decreased risk of severe P. falciparum malaria in individuals with haemoglobin AS (OR 0·09, 95% CI 0·06-0·12), haemoglobin CC (0·27, 0·11-0·63), haemoglobin AC (0·83, 0·67-0·96), homozygous α-thalassaemia (0·63, 0·48-0·83), and heterozygous..."

Meta-analysis provides strong human clinical evidence for marked severe-malaria protection in HbAS.

PMID:23035141 SUPPORT Human Clinical

"Although sickle cell trait protects against severe disease due to Plasmodium falciparum, it has not been clear whether sickle trait also protects against asymptomatic infection (parasitemia)."

Confirms HbAS as a major protective modifier in falciparum malaria.

G6PD (Protective modifier and pharmacogenomic risk factor)

Show evidence (2 references)

PMID:17355169 SUPPORT Human Clinical

"Our results indicate that the uniform state of G6PD deficiency in hemizygous male children conferred significant protection against severe, life-threatening malaria, and that it may have likewise protected homozygous female children."

Case-control evidence supports genotype-specific protection from severe malaria.

PMID:24372186 SUPPORT Human Clinical

"It is now clear that it is not good practice to give one of these drugs before testing a person for his/her G6PD status, especially in populations in whom G6PD deficiency is common."

Supports clinically important pharmacogenomic implications for primaquine safety.

ACKR1 (Duffy antigen receptor for chemokines) (Strong protective modifier for Plasmodium vivax)

Show evidence (2 references)

PMID:30218021 SUPPORT Human Clinical

"The variants of the Duffy Antigen/Receptor for Chemokines (DARC) gene have probably been selected by malaria parasites, particularly the FY*O allele, which is fixed in sub-Saharan Africa and confers resistance to Plasmodium vivax infection."

Human population genetics evidence supports Duffy-null resistance against vivax malaria.

PMID:37399221 PARTIAL Human Clinical

"This study confirms that Duffy-negativity does not provide complete protection against P. vivax infection."

Adds modern nuance that protection is strong but not absolute in all endemic contexts.

HBB (HbC) (Protective)

Show evidence (1 reference)

PMID:15295709 SUPPORT Human Clinical

"HbAC did not prevent infection but reduced the odds of developing severe malaria and severe anemia."

Case-control data supports protection from severe outcomes despite ongoing infection risk.

HBA1/HBA2 (alpha-thalassemia) (Protective)

Show evidence (1 reference)

PMID:22445352 SUPPORT Human Clinical

"Meta-analysis of case-control studies showed a decreased risk of severe P. falciparum malaria in individuals with haemoglobin AS (OR 0·09, 95% CI 0·06-0·12), haemoglobin CC (0·27, 0·11-0·63), haemoglobin AC (0·83, 0·67-0·96), homozygous α-thalassaemia (0·63, 0·48-0·83), and heterozygous..."

Meta-analysis shows significant protective effects for alpha-thalassemia genotypes.

HBB (beta-thalassemia trait) (Protective (lower parasitemia))

Show evidence (2 references)

PMID:8846492 SUPPORT Human Clinical

"The mean parasitaemia levels of patients with alpha- or beta-thalassaemia trait or with severe glucose-6-phosphate dehydrogenase (G6PD) deficiency were lower than those of individuals with normal haemoglobin AA or with heterozygous haemoglobin E."

Human observational data supports reduced parasitemia in beta-thalassemia trait.

PMID:22445352 PARTIAL Human Clinical

"Few clinical studies have investigated β-thalassaemia, haemoglobin E, P. vivax malaria, or pregnancy-associated malaria."

Indicates supporting literature is more limited than for other major malaria-protective polymorphisms.

ABO (Susceptibility)

Show evidence (1 reference)

PMID:37708213 SUPPORT Human Clinical

"In the case-control study, compared to OO, the double dose genotypes consistently had higher odds ratios (OR) for severe malaria than single dose genotypes, with AB (OR 1.93) and AO (OR 1.27) showing most marked difference (p = 0.02, Wald test)."

Human case-control data support increased severe-malaria risk in double-dose non-O genotypes.

💊

Treatments

6

Artemisinin-based antimalarial therapy

Action: pharmacotherapy MAXO:0000058

Oral or parenteral artemisinin-based therapy remains the treatment mainstay for malaria.

Show evidence (1 reference)

PMID:37924827 SUPPORT Human Clinical

"Parasitological diagnosis and treatment with oral or parenteral artemisinin-based therapy is the mainstay of patient management."

Directly supports frontline antimalarial pharmacotherapy.

Primaquine radical cure for vivax malaria

Action: pharmacotherapy MAXO:0000058

Primaquine reduces recurrent vivax malaria by targeting dormant liver hypnozoites.

Mechanism Target:

INHIBITS Hypnozoite persistence and vivax relapse — Primaquine targets dormant hypnozoites to reduce recurrent episodes.

Show evidence (1 reference)

PMID:37748496 SUPPORT Human Clinical

"Increasing the total dose of primaquine from 3·5 mg/kg to 7 mg/kg can reduce P vivax recurrences by more than 50% in most endemic regions"

Supports mechanism-linked reduction in relapse burden.

Show evidence (1 reference)

PMID:37748496 SUPPORT Human Clinical

"Compared with treatment without primaquine, the rate of P vivax recurrence was lower after treatment with low-dose primaquine (adjusted hazard ratio 0·21, 95% CI 0·17-0·27; p<0·0001) and high-dose primaquine (0·10, 0·08-0·12; p<0·0001)."

Demonstrates major recurrence-risk reduction with primaquine.

Supportive care in severe malaria

Action: supportive care MAXO:0000950

Severe malaria management includes organ support and restrictive fluid strategy to improve survival.

Show evidence (1 reference)

PMID:37924827 SUPPORT Human Clinical

"Timely blood transfusion, renal replacement therapy, and restrictive fluid therapy can improve survival in severe malaria."

Supports critical-care supportive interventions in severe disease.

Insecticide-treated bed nets

Action: medical action MAXO:0000001

Insecticide-treated bed nets are a core vector-control intervention that reduces malaria burden by limiting mosquito exposure.

Show evidence (1 reference)

PMID:22445352 SUPPORT Human Clinical

"including intermittent preventive antimalarial therapy in children (87% to 69%)74,75 or infants (38%)76 and the use of insecticide-treated bed nets (45%).77"

Human epidemiologic synthesis identifies insecticide-treated bed nets as a major malaria-control intervention.

Intermittent preventive treatment and seasonal chemoprevention

Action: pharmacotherapy MAXO:0000058

Drug-based preventive strategies such as IPTp and seasonal chemoprevention reduce malaria morbidity in high-risk populations.

Show evidence (1 reference)

PMID:37924827 SUPPORT Human Clinical

"Rigorous use of intermittent preventive treatment in pregnancy and infancy and seasonal chemoprevention, potentially combined with pre-erythrocytic vaccines endorsed by WHO in 2021 and 2023, can substantially reduce malaria morbidity."

Directly supports IPTp/infancy preventive treatment and seasonal chemoprevention as morbidity-reducing strategies.

Pre-erythrocytic malaria vaccination (RTS,S and R21)

Action: vaccination MAXO:0001017

WHO-endorsed pre-erythrocytic vaccines are deployed to reduce clinical malaria burden in endemic pediatric populations.

Show evidence (1 reference)

PMID:37924827 SUPPORT Human Clinical

"Rigorous use of intermittent preventive treatment in pregnancy and infancy and seasonal chemoprevention, potentially combined with pre-erythrocytic vaccines endorsed by WHO in 2021 and 2023, can substantially reduce malaria morbidity."

Supports clinical deployment of RTS,S (2021) and R21 (2023) era malaria vaccines as morbidity-reduction interventions.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Malaria:

Dengue disease MONDO:0005502

Overlapping Features Mosquito-borne viral febrile illness that frequently overlaps clinically with malaria in tropical settings.

Distinguishing Features

Prominent retro-orbital pain, rash, and severe myalgia are more typical of dengue.
Plasma leakage and hemoconcentration with severe thrombocytopenia support severe dengue.
Dengue NS1 antigen or serology supports dengue over malaria when blood film/RDT for malaria is negative.

Show evidence (1 reference)

PMID:27759344 SUPPORT Human Clinical

"Moreover it is a great mimic of co-existing epidemics like Malaria, Chikungunya and Zika virus disease, which are also mosquito-borne diseases."

Review explicitly identifies dengue as a clinical mimic of malaria in co-endemic settings.

chikungunya MONDO:0017941

Overlapping Features Arboviral febrile illness that can be confused with malaria, especially during outbreaks.

Distinguishing Features

Severe incapacitating polyarthralgia with prolonged joint symptoms is more characteristic of chikungunya.
Maculopapular rash is common and cyclic parasitemia is absent.
Chikungunya PCR/serology with negative malaria parasitology supports chikungunya.

Show evidence (1 reference)

PMID:27759344 SUPPORT Human Clinical

"Moreover it is a great mimic of co-existing epidemics like Malaria, Chikungunya and Zika virus disease, which are also mosquito-borne diseases."

Supports chikungunya as an overlapping mosquito-borne differential diagnosis for malaria.

typhoid fever Not Yet Curated MONDO:0005619

Overlapping Features Invasive Salmonella infection causing prolonged fever that can resemble uncomplicated malaria.

Distinguishing Features

Sustained stepwise fever pattern with abdominal symptoms and enteric features.
Positive blood culture for Salmonella Typhi supports typhoid fever.
Lack of malaria parasitemia on repeated testing argues against malaria.

Show evidence (1 reference)

PMID:26261776 SUPPORT Human Clinical

"Since the symptoms and signs are non-specific and resemble other tropical infections like malaria, enteric fever, dengue or leptospirosis, appropriate laboratory tests are necessary to confirm diagnosis."

Directly identifies enteric fever (typhoid) as a key tropical differential when evaluating malaria-like febrile illness.

leptospirosis MONDO:0005825

Overlapping Features Zoonotic bacterial febrile illness with multiorgan involvement that can mimic severe malaria.

Distinguishing Features

Exposure to contaminated water or animal urine supports leptospirosis risk.
Conjunctival suffusion, jaundice, and acute kidney injury are suggestive in severe cases.
Positive leptospira serology/PCR with negative malaria parasitology supports leptospirosis.

Show evidence (1 reference)

PMID:26261776 SUPPORT Human Clinical

"Since the symptoms and signs are non-specific and resemble other tropical infections like malaria, enteric fever, dengue or leptospirosis, appropriate laboratory tests are necessary to confirm diagnosis."

Supports leptospirosis as a common mimic requiring targeted testing in malaria-like presentations.

📊

Related Datasets

3

Whole blood transcriptome of childhood malaria geo:GSE1124

Whole-blood microarray profiling across asymptomatic infection, uncomplicated malaria, severe malarial anemia, cerebral malaria, and healthy controls in African children.

human MICROARRAY n=47 Affymetrix Human Genome U133A and...

whole blood

Conditions: asymptomatic Plasmodium falciparum infection uncomplicated malaria severe malarial anemia cerebral malaria healthy controls

PMID:30638864

GEO series metadata reports pooled whole-blood expression profiling across pediatric malaria severity strata.

Blood transcriptional profiles discriminates cerebral and mild malaria patient living in Senegal geo:GSE116306

PBMC microarray profiling comparing mild and cerebral malaria at clinical presentation in Senegalese participants.

human MICROARRAY n=16 Agilent SurePrint G3 Human GE 8x60K...

peripheral blood mononuclear cell

Conditions: mild malaria cerebral malaria

GEO series metadata indicates no linked PubMed citation currently recorded in GEO.

Whole-blood transcriptional signatures composed of erythropoietic and Nrf2-regulated genes differ between cerebral malaria and severe malarial anemia geo:GSE117613

Whole-blood transcriptome microarray study in Ugandan children comparing cerebral malaria, severe malarial anemia, and community controls without P. falciparum infection.

human MICROARRAY n=46 Illumina HumanHT-12 v4 Expression BeadChip

whole blood

Conditions: cerebral malaria severe malarial anemia community control without Plasmodium falciparum infection

PMID:30060095

Captures host whole-blood transcriptional differences between major severe-malaria syndromes.

🔬

Clinical Trials

3

NCT04704830 PHASE_III UNKNOWN

Phase III multicenter trial evaluating efficacy of R21/Matrix-M in African children.

Target Phenotypes: Fever ↗

Show evidence (1 reference)

clinicaltrials:NCT04704830 SUPPORT Human Clinical

"A Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria"

Trial registry evidence for phase III vaccine efficacy evaluation in malaria.

NCT04158713 PHASE_III UNKNOWN

Placebo-controlled chemoprevention trial of monthly dihydroartemisinin-piperaquine in HIV-infected pregnant participants on cotrimoxazole.

Target Phenotypes: Fever ↗ Anemia ↗

Show evidence (1 reference)

clinicaltrials:NCT04158713 SUPPORT Human Clinical

"This is a 2-arm, individually-randomized, multi-centre, placebo-controlled superiority trial comparing the safety and efficacy of daily CTX plus monthly DP ('CTX-DP') versus daily CTX plus monthly placebo-DP (i.e. 'CTX-alone', control arm) to reduce malaria and the adverse effects of malaria in..."

Registry record supports active clinical testing of preventive pharmacotherapy in a high-risk population.

NCT05019729 PHASE_I UNKNOWN

Phase I controlled human malaria infection study evaluating safety and protective efficacy of anti-malaria monoclonal antibody L9LS.

Target Phenotypes: Fever ↗

Show evidence (1 reference)

clinicaltrials:NCT05019729 SUPPORT Human Clinical

"Most participants took part in the controlled human malaria infection (CHMI) or malaria challenge to find out if L9LS prevents malaria after being bitten by infected mosquitos."

Registry evidence supports early-phase interventional prevention trial design.

📚

Literature Summaries

1

Falcon ▸

Disease Pathophysiology Research Template

Edison Scientific Literature 31 citations 2026-02-19T22:25:10.749297

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

Disease Name: Malaria
MONDO ID: (if available)
Category: Infectious

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Malaria. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

What are the primary pathophysiological mechanisms?
What molecular pathways are dysregulated?
What cellular processes are affected?

2. Key Molecular Players

Genes/Proteins: Which genes are causally involved or implicated?
Chemical Entities: What metabolites, drugs, or small molecules are relevant?
Cell Types: Which cell types are primarily affected?
Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

What biological processes (GO terms) are disrupted?
Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

Where in the cell do key processes occur?
Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

What is the sequence of events from initial trigger to clinical manifestation?
Are there distinct stages or phases?

6. Phenotypic Manifestations

What are the key clinical phenotypes?
How do they relate to the underlying mechanisms?

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic claims
Prioritize recent reviews and landmark papers
Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Title: Molecular and Cellular Pathophysiology of Malaria (Plasmodium falciparum and Plasmodium vivax) — 2024 Update

Disease: Malaria (infectious disease; apicomplexan protozoa of genus Plasmodium). MONDO ID: Not established from the retrieved sources in this run.

Key concepts and definitions (current understanding)

1.1 Core life-cycle stages relevant to pathophysiology Malaria pathophysiology is stage-specific: (i) liver-stage infection establishes infection after sporozoite inoculation, with clinically silent development in hepatocytes; (ii) blood-stage asexual replication drives nearly all acute clinical disease; and (iii) in P. vivax (and P. ovale) a dormant liver-stage “hypnozoite” reservoir can reactivate and drive relapses, shaping chronic/recurrent disease and transmission dynamics. The importance of hypnozoite-driven relapse is quantified in recent clinical synthesis: an estimated 66–95% of P. vivax cases are relapses originating from liver hypnozoites. (commons2024effectofprimaquine pages 1-2)

1.2 Sequestration/cytoadherence and microvascular dysfunction (hallmark of severe P. falciparum) A defining mechanistic concept in severe falciparum malaria is cytoadherence and sequestration of Plasmodium falciparum-infected erythrocytes (iRBCs) in post-capillary venules and microvessels. This process (a) allows iRBCs to evade splenic clearance and (b) produces tissue hypoperfusion, endothelial activation, barrier dysfunction (e.g., blood–brain barrier disruption), and inflammatory/coagulopathic cascades. PfEMP1 (Plasmodium falciparum erythrocyte membrane protein 1) is a major parasite adhesin mediating this binding to host endothelial receptors including ICAM1 and EPCR. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83, gopinadhan2024ahumanpluripotent pages 8-10)

1.3 Antigenic variation PfEMP1 is encoded by a ~60-member var gene family, enabling antigenic variation and receptor-binding diversity, which contributes to immune evasion and tissue-specific sequestration phenotypes. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83)

1.4 Hemolysis, anemia, and malaria toxins Blood-stage infection causes destruction of parasitized and non-parasitized erythrocytes, impaired erythropoiesis (“dyserythropoiesis”), hypersplenism, and inflammatory iron restriction, driving malarial anemia. A key parasite-derived bioactive “toxin-like” product is hemozoin (Hz; malaria pigment), formed during hemoglobin digestion, which accumulates in organs and modulates innate immune signaling and oxidative pathways. (blankson2024understandingthepathogenesisa pages 80-83, blankson2024understandingthepathogenesis pages 78-80)

Core pathophysiology (molecular/cellular mechanisms)

2.1 Sequestration/cytoadherence → endothelial activation → barrier failure

Parasite and host ligands/receptors • Parasite: PfEMP1/var gene products displayed on iRBC surfaces mediate adhesion to endothelial receptors including ICAM1 and EPCR. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83) • Host endothelium: ICAM-1 (HGNC:5344; gene ICAM1) and VCAM-1 (HGNC:12663; gene VCAM1) are endothelial adhesion molecules upregulated during inflammatory activation and are measurably increased in in vitro BBB models after exposure to Pf-iRBCs. (gopinadhan2024ahumanpluripotent pages 8-10)

EPCR pathway perturbation EPCR (endothelial protein C receptor; gene PROCR) is implicated in severe malaria; PfEMP1 binding to EPCR is described as disrupting EPCR’s anti-inflammatory/cytoprotective functions, providing a mechanistic link to endothelial injury in cerebral malaria. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83, wassmer2024unravellingmysteriesat pages 12-14)

BBB disruption (cellular process and quantitative evidence) A 2024 in vitro BBB model using hiPSC-derived brain microvascular endothelial cells demonstrated functional barrier breakdown after co-culture with Pf-iRBCs (HB3var03 strain). Key quantitative findings included: baseline barrier tightness (TEER ~1200 Ω·cm2 in hiPSC-BMECs vs ~100 Ω·cm2 in immortalized cells), and after 6 hours of Pf-iRBC exposure, reduced TEER and increased sodium fluorescein permeability (paracellular leak), accompanied by increased ICAM-1 and VCAM-1 expression. (gopinadhan2024ahumanpluripotent pages 8-10, gopinadhan2024ahumanpluripotent media b2e9c3aa)

2.2 Inflammation, cytokines, innate sensing, and immunopathology

Cytokine dysregulation Severe malaria is associated with dysregulated pro-inflammatory cytokines and stress pathways including TNF-α, IFNγ, IL-1, IL-6, MIF, and HIF-1; imbalance of regulatory cytokines (e.g., low IL-10/IL-12 in severe malarial anemia) is also described. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83)

Hemozoin-triggered innate activation and metalloprotease involvement Hemozoin accumulates in organs (liver, spleen, lungs, brain) and, when phagocytosed by monocytes, can induce TNFα and IL-1β and increase MMP-9 activity; MMP-9 is described as capable of degrading basement membranes and disrupting endothelial tight junctions, consistent with a BBB injury mechanism. (blankson2024understandingthepathogenesis pages 78-80)

DNA/Hz sensing and inflammasome activation In a placental malaria model summary, hemozoin complexed with DNA is described as activating NLRP3 and TLR9, inducing IL-1β and type I interferon signaling, linking parasite products to innate inflammatory programs and (context-dependent) immune suppression with chronic elevation. (ekregbesi2024developingaphysiologic pages 13-16)

Neutrophils and NETs Neutrophil extracellular trap (NET) formation in response to infected erythrocytes is described as requiring CXCR4 and MIF, linking chemokine receptor signaling and inflammatory mediators to microvascular immunopathology. (blankson2024understandingthepathogenesis pages 220-224, blankson2024understandingthepathogenesisa pages 220-224)

2.3 Hemolysis, oxidative stress, and anemia mechanisms

Erythropoiesis inhibition by circulating hemozoin A 2024 severe malaria review summarizes that circulating hemozoin at ~1–10 µg/mL can directly inhibit erythropoiesis, and can induce lipid oxidation products (15-HETE, 4HNE) that stiffen RBCs and shorten RBC lifespan, consistent with combined production-loss anemia. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83)

Splenic clearance/hypersplenism Hypersplenism and enhanced splenic clearance/removal of RBCs is described as contributing to anemia and can persist for weeks. (blankson2024understandingthepathogenesisa pages 80-83)

Metabolic derangements (hypoglycemia/lactate) A placental malaria model summary links ROS-driven mitochondrial dysfunction and increased glycolysis to hyperlactatemia, hypoglycemia, and tissue hypoxia/necrosis, providing a mechanistic bridge between inflammatory/oxidative programs and systemic metabolic complications. (ekregbesi2024developingaphysiologic pages 13-16)

Key molecular players and entities (knowledge-base oriented)

3.1 Parasite genes/proteins (Plasmodium) • PfEMP1 (variant surface antigen family): mediates cytoadherence to ICAM1/EPCR; encoded by ~60 var genes; antigenic variation and receptor-binding diversity. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83) • var gene family: encodes PfEMP1; central to immune evasion and tissue-specific pathology via differential receptor binding. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83)

3.2 Host genes/proteins (HGNC) implicated in mechanisms • ICAM1 (HGNC:5344): endothelial receptor and marker of endothelial activation; upregulated in BBB model after Pf-iRBC exposure. (gopinadhan2024ahumanpluripotent pages 8-10) • VCAM1 (HGNC:12663): endothelial activation marker; increased in BBB model after Pf-iRBC exposure. (gopinadhan2024ahumanpluripotent pages 8-10) • PROCR / EPCR: receptor for protein C with cytoprotective roles; implicated in severity and PfEMP1 binding-mediated dysfunction. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83, wassmer2024unravellingmysteriesat pages 12-14) • CXCR4 (HGNC:2561): required for NET formation in response to infected erythrocytes (mechanistic role in inflammatory pathology). (blankson2024understandingthepathogenesis pages 220-224) • MIF (HGNC:7097): elevated inflammatory mediator linked to NET formation and severe malaria immunopathology. (blankson2024understandingthepathogenesis pages 220-224, blankson2024understandingthepathogenesisa pages 220-224) • MMP9 (HGNC:7176): induced/activated in hemozoin-exposed monocytes; mechanistically linked to basement membrane/tight junction disruption. (blankson2024understandingthepathogenesis pages 78-80) • TLR9 (HGNC:15633) and NLRP3 (HGNC:16400): described as sensing pathways engaged by hemozoin+DNA, driving IL-1β/type I IFN programs. (ekregbesi2024developingaphysiologic pages 13-16) • TNF (HGNC:11892), IFNG (HGNC:5438), IL1B (HGNC:5992), IL6 (HGNC:6018): cytokines highlighted in severe malaria inflammatory dysregulation. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83, blankson2024understandingthepathogenesis pages 78-80)

Disease–target associations (Open Targets, supportive/triage evidence) Open Targets lists malaria associations for TLR9, TLR7, ABO, and several MMPs (e.g., MMP8), with example literature PMIDs for ABO-malaria associations including 37708213 (PMC10522014) among others. (gopinadhan2024ahumanpluripotent media b2e9c3aa)

3.3 Cell types (CL) primarily involved (mechanistically) • Brain microvascular endothelial cell (BBB endothelium): barrier integrity loss and adhesion molecule upregulation in response to Pf-iRBC exposure. (gopinadhan2024ahumanpluripotent pages 8-10) • Monocyte/macrophage (phagocytes): hemozoin uptake drives cytokine release and MMP activity. (blankson2024understandingthepathogenesis pages 78-80) • Neutrophil: NET formation implicated in severe malaria inflammation. (blankson2024understandingthepathogenesis pages 220-224) • Erythrocyte: infected and uninfected RBC destruction, altered deformability (oxidative lipid products), and sequestration. (blankson2024understandingthepathogenesisa pages 80-83)

3.4 Anatomical locations (UBERON) involved • Liver: hypnozoite reservoir (vivax/ovale) and hemozoin accumulation. (commons2024effectofprimaquine pages 1-2, blankson2024understandingthepathogenesis pages 78-80) • Spleen: clearance/hypersplenism and hemozoin accumulation. (blankson2024understandingthepathogenesisa pages 80-83, blankson2024understandingthepathogenesis pages 78-80) • Brain microvasculature/BBB: cerebral malaria sequestration and barrier dysfunction. (wassmer2024unravellingmysteriesat pages 12-14, gopinadhan2024ahumanpluripotent pages 8-10) • Placenta: sequestration-driven pathology in pregnancy-associated malaria models. (ekregbesi2024developingaphysiologic pages 13-16)

3.5 Chemical entities (CHEBI-relevant) • Hemozoin (malaria pigment): inhibits erythropoiesis; immunomodulatory; organ deposition. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesis pages 78-80) • Sodium fluorescein: permeability tracer used to quantify BBB leak in vitro. (gopinadhan2024ahumanpluripotent pages 8-10, gopinadhan2024ahumanpluripotent media b2e9c3aa) • 15-HETE and 4HNE (lipid oxidation products): associated with RBC stiffening/shortened RBC lifespan in severe malarial anemia context. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83)

Biological processes disrupted (GO-oriented) Representative disrupted biological processes supported by the retrieved evidence include: • Cell adhesion / cytoadherence (iRBC–endothelium binding): PfEMP1–ICAM1/EPCR mediated adhesion and sequestration. (blankson2024understandingthepathogenesis pages 80-83, gopinadhan2024ahumanpluripotent pages 8-10) • Endothelial cell activation and inflammatory signaling (e.g., TNF/IFNγ-driven programs; adhesion molecule upregulation): increased ICAM1/VCAM1, cytokine dysregulation. (blankson2024understandingthepathogenesis pages 80-83, gopinadhan2024ahumanpluripotent pages 8-10) • Regulation of vascular permeability / barrier function: reduced TEER and increased paracellular permeability in BBB model. (gopinadhan2024ahumanpluripotent pages 8-10, gopinadhan2024ahumanpluripotent media b2e9c3aa) • Innate immune response and inflammasome activation (TLR9/NLRP3; IL-1β; type I IFN): hemozoin+DNA sensing. (ekregbesi2024developingaphysiologic pages 13-16) • Matrix remodeling / basement membrane organization (MMP-9 activity): hemozoin-associated MMP-9 induction and barrier disruption mechanism. (blankson2024understandingthepathogenesis pages 78-80) • Erythrocyte homeostasis / erythropoiesis: hemozoin inhibition of erythropoiesis and anemia pathogenesis. (blankson2024understandingthepathogenesis pages 80-83) • Neutrophil extracellular trap formation: CXCR4/MIF-dependent NET release to infected erythrocytes. (blankson2024understandingthepathogenesis pages 220-224)
Cellular components (where processes occur; GO-CC oriented) • Plasma membrane / cell surface (iRBC surface PfEMP1; endothelial ICAM1/EPCR/VCAM1). (blankson2024understandingthepathogenesis pages 80-83, gopinadhan2024ahumanpluripotent pages 8-10) • Microvascular lumen and endothelium interface (sequestration site). (wassmer2024unravellingmysteriesat pages 12-14, gopinadhan2024ahumanpluripotent pages 8-10) • Tight junction-associated structures of endothelial cells (occludin/ZO-1/claudin-5 localization disruption reported in BBB model). (gopinadhan2024ahumanpluripotent pages 8-10) • Extracellular space / circulating plasma (soluble receptor forms; extracellular vesicles; microparticles; cytokines). (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesis pages 220-224) • Phagolysosomal compartments (hemozoin phagocytosis by monocytes/macrophages). (blankson2024understandingthepathogenesis pages 78-80)
Disease progression (sequence of events)

6.1 P. falciparum (typical progression to severe disease) 1) Blood-stage infection expands; iRBCs display variant surface antigens (PfEMP1). (blankson2024understandingthepathogenesis pages 80-83) 2) iRBC cytoadherence to endothelial receptors (ICAM1/EPCR) → sequestration → reduced microvascular flow and hypoperfusion. (blankson2024understandingthepathogenesis pages 80-83, gopinadhan2024ahumanpluripotent pages 8-10) 3) Endothelial activation and barrier dysfunction: adhesion molecules upregulated; BBB tight junction localization disrupted; permeability increases. (gopinadhan2024ahumanpluripotent pages 8-10, gopinadhan2024ahumanpluripotent media b2e9c3aa) 4) Hemolysis and hemozoin release/uptake → cytokine amplification (TNFα/IL-1β), MMP activity (MMP-9), and oxidative injury pathways. (blankson2024understandingthepathogenesis pages 78-80, blankson2024understandingthepathogenesis pages 80-83) 5) Organ-specific syndromes emerge (e.g., cerebral malaria with BBB breakdown and neurologic manifestations; placental malaria). (wassmer2024unravellingmysteriesat pages 12-14, ekregbesi2024developingaphysiologic pages 13-16)

6.2 P. vivax (relapsing biology) 1) Acute blood-stage infection causes febrile illness and hematologic effects. 2) Dormant hypnozoites persist in liver and can reactivate, producing relapses that cumulatively erode health and sustain transmission; relapse dominates recurrence burden. (commons2024effectofprimaquine pages 1-2) 3) Radical cure requires 8-aminoquinolines (primaquine/tafenoquine) that target hypnozoites but carry hemolysis risk in G6PD deficiency. (brito2024operationaleffectivenessof pages 1-3, commons2024effectofprimaquine pages 1-2)

Phenotypic manifestations (HP-oriented; mechanistic links) • Fever (systemic inflammatory response; cytokines). (blankson2024understandingthepathogenesis pages 78-80) • Anemia / severe malarial anemia (hemolysis + impaired erythropoiesis + hypersplenism; hemozoin inhibition of erythropoiesis; oxidative lipid products). (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesisa pages 80-83) • Cerebral malaria phenotypes: coma, seizures, neurologic sequelae (linked to sequestration, BBB disruption, endothelial activation, inflammation/coagulation). (wassmer2024unravellingmysteriesat pages 12-14, gopinadhan2024ahumanpluripotent pages 8-10) • Hypoglycemia / hyperlactatemia (linked to oxidative stress/mitochondrial dysfunction and metabolic shifts). (ekregbesi2024developingaphysiologic pages 13-16)
Recent developments and latest research (prioritizing 2023–2024)

8.1 High-fidelity in vitro BBB models for mechanistic and therapeutic discovery (2024) The 2024 hiPSC-derived BBB model improves physiologic relevance by achieving high baseline TEER and demonstrating rapid Pf-iRBC-induced barrier leak with concurrent adhesion molecule induction, providing a platform for dissecting endothelial injury mechanisms and screening interventions. Figure 1 (schematic + TEER + permeability data) consolidates these endpoints. Publication: May 2024; URL/DOI: https://doi.org/10.1186/s12987-024-00541-9. (gopinadhan2024ahumanpluripotent pages 8-10, gopinadhan2024ahumanpluripotent media b2e9c3aa)

8.2 Systems-level reframing of cerebral malaria pathology (2024 review) A 2024 Trends in Parasitology review highlights multi-compartment and perivascular-space concepts in cerebral malaria, emphasizing that neuropathology arises from host and parasite factors including endothelial dysfunction and dysregulated immune responses. It cites multiple mechanistic studies with PubMed IDs, including EPCR association with severity (Bernabeu & Smith; PMID 27939609), and CD8+ T cell involvement (Riggle et al.; PMID 31821175). Publication: Jan 2024; URL/DOI: https://doi.org/10.1016/j.pt.2023.11.005. (wassmer2024unravellingmysteriesat pages 12-14)

8.3 Quantitative modern synthesis of vivax relapse biology and primaquine dose–response (2023 online / 2024 print) A 2024 Lancet Infectious Diseases individual-patient-data meta-analysis (published online Sept 22, 2023; Feb 2024 issue) provides dose–response evidence that higher total primaquine dosing substantially reduces recurrence risk at day 180 (51.0% without primaquine; 19.3% low total dose; 8.1% high total dose), with adjusted hazard ratios vs no primaquine of 0.21 (low-dose) and 0.10 (high-dose). URL/DOI: https://doi.org/10.1016/S1473-3099(23)00430-9. (commons2024effectofprimaquine pages 1-2)

8.4 Real-world radical cure implementation for vivax: tafenoquine/primaquine rollout (2024) A 2024 Lancet Infectious Diseases operational study in Brazil describes real-world deployment of tafenoquine alongside quantitative G6PD screening (TRuST rollout), with follow-up for recurrences up to day 180 using linked surveillance records, across 43 health-care centres (Sept 2021–Aug 2022). It contextualizes prior trial evidence including ~70% reduction in recurrence vs placebo, and emphasizes hemolysis risk management via G6PD testing. Publication: Jun 2024; URL/DOI: https://doi.org/10.1016/S1473-3099(24)00074-4. (brito2024operationaleffectivenessof pages 1-3)

8.5 Prevention innovations: monoclonal antibody prophylaxis in endemic settings (2024) A phase 2 NEJM trial in Mali evaluated subcutaneous L9LS in children (6–10 years) during a 6-month malaria season. Quantitative efficacy results: P. falciparum infection occurred in 81% of placebo vs 48% (150 mg) and 40% (300 mg), yielding efficacy of 66% and 70% against infection, and 67% and 77% against clinical malaria, respectively. Publication: May 2024; URL/DOI: https://doi.org/10.1056/NEJMoa2312775. (brito2024operationaleffectivenessof pages 1-3)

Current applications and real-world implementations

9.1 Global burden context (WHO 2023 data summarized in 2024 sources) Multiple 2024 sources summarizing the WHO World Malaria Report 2023 converge on: 249 million malaria cases and 608,000 deaths in 2022, with strong concentration in Africa and in young children. A directly quotable sentence from a 2024 SMC implementation paper states: “Globally, an estimated 249 million malaria cases occurred in 2022, leading to 608,000 malaria deaths in a single year.” (Jan 2024; DOI: https://doi.org/10.58614/jahsm481). (musa2024impactandacceptability pages 1-2) A 2024 World Malaria Report summary article with DOI provides additional distributional details: children under 5 years accounted for 76% of malaria deaths in 2022, and Africa contributed ~233 million cases (93.6% of global cases). Publication: Jun 2024; URL/DOI: https://doi.org/10.56786/phwr.2024.17.32.1. (shin20242023worldmalaria pages 1-4)

9.2 Radical cure programs (P. vivax) Implementation of tafenoquine in Brazil is an example of health-system translation of pathophysiology (hypnozoite eradication) into practice, integrating point-of-care quantitative G6PD testing to mitigate hemolysis risk and using surveillance databases to assess recurrence through day 180. (brito2024operationaleffectivenessof pages 1-3)

9.3 Endothelial/BBB platforms for therapeutic testing The hiPSC-BBB cerebral malaria model provides a practical experimental system that can be used to test interventions aimed at preventing iRBC-induced barrier breakdown (e.g., anti-adhesion therapies, anti-inflammatory strategies, barrier stabilizers), using TEER and fluorescein permeability as quantitative endpoints. (gopinadhan2024ahumanpluripotent pages 8-10, gopinadhan2024ahumanpluripotent media b2e9c3aa)

Expert opinion and authoritative analysis (from 2024 sources)

10.1 Mechanistic consensus on cerebral malaria drivers The Trends in Parasitology review frames cerebral malaria as a multi-factorial syndrome involving “host and parasite factors, with endothelial dysfunction” and highlights EPCR-related severity, immune cell contributions (including CD8+ T cells), and extracellular vesicle-mediated vascular effects, emphasizing that neuropathology cannot be reduced to a single adhesion interaction. (wassmer2024unravellingmysteriesat pages 12-14)

10.2 Radical cure as a hypnozoite-targeting imperative The 2024 Lancet Infectious Diseases IPD meta-analysis and the Brazil operational study both reinforce that eliminating hypnozoites is central for preventing recurrence/relapse, but that implementation must address hemolysis risks (G6PD deficiency) and adherence feasibility. (brito2024operationaleffectivenessof pages 1-3, commons2024effectofprimaquine pages 1-2)

Key statistics and data (recent)

Global epidemiology (WHO 2023 WMR, as summarized in 2024 publications) • 2022 global malaria burden: ~249 million cases; ~608,000 deaths. (shin20242023worldmalaria pages 1-4, musa2024impactandacceptability pages 1-2) • Under-5 mortality share: 76% of malaria deaths in 2022 were in children under 5 years. (shin20242023worldmalaria pages 1-4)

Vivax relapse biology and primaquine effect sizes • Estimated 66–95% of vivax cases are relapses from hypnozoites. (commons2024effectofprimaquine pages 1-2) • Recurrence risk at day 180: 51.0% without primaquine vs 19.3% (low total dose) vs 8.1% (high total dose). (commons2024effectofprimaquine pages 1-2) • Adjusted hazard ratio vs no primaquine: 0.21 (low dose) and 0.10 (high dose). (commons2024effectofprimaquine pages 1-2)

BBB disruption model (P. falciparum) • Baseline TEER: hiPSC-BMECs ~1200 Ω·cm2 vs immortalized cells ~100 Ω·cm2; Pf-iRBC exposure causes TEER drop and fluorescein permeability increase at ~6 h. (gopinadhan2024ahumanpluripotent pages 8-10, gopinadhan2024ahumanpluripotent media b2e9c3aa)

Severe malarial anemia and hemozoin • Circulating hemozoin: ~1–10 µg/mL reported, with direct erythropoiesis inhibition and oxidative lipid product induction (15-HETE, 4HNE) linked to RBC stiffening and shortened lifespan. (blankson2024understandingthepathogenesis pages 80-83)

Evidence items with PMIDs (when available from retrieved sources)

• EPCR association with severe malaria (cited in Wassmer et al. 2024 review): Bernabeu & Smith; PMID 27939609. (wassmer2024unravellingmysteriesat pages 12-14) • CD8+ T cell targeting of cerebrovasculature in cerebral malaria (cited in Wassmer et al. 2024 review): Riggle et al.; PMID 31821175. (wassmer2024unravellingmysteriesat pages 12-14) • ABO association evidence is listed in Open Targets with example PMIDs including 37708213 (PMC10522014). (gopinadhan2024ahumanpluripotent media b2e9c3aa)

Note: Several key mechanistic claims in this report come from 2024 reviews that cite primary literature (PMIDs), but the full primary articles themselves were not directly retrieved in this run; therefore, additional PMIDs for each mechanistic sub-claim (e.g., specific PfEMP1 domain interactions, coagulation pathway components) should be curated from the reference lists of these reviews during knowledge-base ingestion. (wassmer2024unravellingmysteriesat pages 12-14, blankson2024understandingthepathogenesis pages 80-83)

Appendix A. Ontology-ready annotation suggestions (seed set)

A1. Genes/proteins (HGNC) • ICAM1; VCAM1; PROCR (EPCR); TNF; IFNG; IL1B; IL6; CXCR4; MIF; MMP9; TLR9; NLRP3. (blankson2024understandingthepathogenesis pages 80-83, blankson2024understandingthepathogenesis pages 78-80, ekregbesi2024developingaphysiologic pages 13-16, gopinadhan2024ahumanpluripotent pages 8-10)

A2. Biological processes (GO) • iRBC cytoadherence / cell adhesion; endothelial activation; regulation of vascular permeability; inflammatory response; cytokine-mediated signaling pathway; inflammasome complex activation; neutrophil extracellular trap formation; erythrocyte homeostasis; regulation of erythrocyte differentiation/erythropoiesis. (blankson2024understandingthepathogenesis pages 78-80, ekregbesi2024developingaphysiologic pages 13-16, gopinadhan2024ahumanpluripotent pages 8-10)

A3. Cellular components (GO-CC) • Endothelial tight junction; plasma membrane; extracellular vesicle/microparticle; extracellular space; basement membrane. (blankson2024understandingthepathogenesis pages 78-80, gopinadhan2024ahumanpluripotent pages 8-10)

A4. Cell types (CL) • Brain microvascular endothelial cell; monocyte; macrophage; neutrophil; erythrocyte. (blankson2024understandingthepathogenesis pages 78-80, gopinadhan2024ahumanpluripotent pages 8-10)

A5. Anatomical entities (UBERON) • Liver; spleen; brain microvasculature/blood–brain barrier; placenta. (blankson2024understandingthepathogenesis pages 78-80, ekregbesi2024developingaphysiologic pages 13-16, gopinadhan2024ahumanpluripotent pages 8-10)

A6. Chemicals (CHEBI) • Hemozoin; sodium fluorescein; 15-HETE; 4HNE; primaquine; tafenoquine; chloroquine. (blankson2024understandingthepathogenesis pages 80-83, brito2024operationaleffectivenessof pages 1-3, gopinadhan2024ahumanpluripotent pages 8-10)

Key cited 2023–2024 sources (URLs, publication dates) • Shin et al. 2024 (Jun 2024). 2023 World Malaria Report summary. Public Health Weekly Report. https://doi.org/10.56786/phwr.2024.17.32.1 (shin20242023worldmalaria pages 1-4) • Dev & Wangdi 2024 (Jun 2024). World Malaria Day editorial. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2024.1433213 (dev2024editorialworldmalaria pages 1-2) • Gopinadhan et al. 2024 (May 2024). BBB model in cerebral malaria. Fluids and Barriers of the CNS. https://doi.org/10.1186/s12987-024-00541-9 (gopinadhan2024ahumanpluripotent pages 8-10) • Wassmer et al. 2024 (Jan 2024). Cerebral malaria perivascular space review. Trends in Parasitology. https://doi.org/10.1016/j.pt.2023.11.005 (wassmer2024unravellingmysteriesat pages 12-14) • Commons et al. 2024 (Feb 2024 issue; online Sept 2023). Primaquine dose IPD meta-analysis. Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(23)00430-9 (commons2024effectofprimaquine pages 1-2) • Brito et al. 2024 (Jun 2024). Tafenoquine/primaquine operational effectiveness in Brazil. Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(24)00074-4 (brito2024operationaleffectivenessof pages 1-3) • Kayentao et al. 2024 (May 2024). L9LS monoclonal antibody prophylaxis. NEJM. https://doi.org/10.1056/NEJMoa2312775 (brito2024operationaleffectivenessof pages 1-3)

Figure citation • Figure: BBB model schematic + TEER reduction + fluorescein permeability increase after Pf-iRBC co-culture (Gopinadhan et al. 2024, Figure 1). (gopinadhan2024ahumanpluripotent media b2e9c3aa)

References

(commons2024effectofprimaquine pages 1-2): Robert J Commons, Megha Rajasekhar, Peta Edler, Tesfay Abreha, Ghulam R Awab, J Kevin Baird, Bridget E Barber, Cindy S Chu, Liwang Cui, André Daher, Lilia Gonzalez-Ceron, Matthew J Grigg, Jimee Hwang, Harin Karunajeewa, Marcus V G Lacerda, Simone Ladeia-Andrade, Kartini Lidia, Alejandro Llanos-Cuentas, Rhea J Longley, Dhelio B Pereira, Ayodhia P Pasaribu, Sasithon Pukrittayakamee, Komal R Rijal, Inge Sutanto, Walter R J Taylor, Pham V Thanh, Kamala Thriemer, José Luiz F Vieira, James A Watson, Lina M Zuluaga-Idarraga, Nicholas J White, Philippe J Guerin, Julie A Simpson, Ric N Price, Bipin Adhikari, Nicholas M Anstey, Ashenafi Assefa, Sarah C Boyd, Nguyen Hoang Chau, Nicholas PJ Day, Tamiru Shibiru Degaga, Arjen M Dondorp, Annette Erhart, Marcelo Urbano Ferreira, Prakash Ghimire, Justin A Green, Gavin CKW Koh, Asrat Hailu Mekuria, Ivo Mueller, Mohammad Nader Naadim, Erni J Nelwan, Francois Nosten, David J Price, Jetsumon Sattabongkot, Kasia Stepniewska, Lorenz von Seidlein, Timothy William, Charles J Woodrow, and Adugna Woyessa. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated plasmodium vivax: a systematic review and individual patient data meta-analysis. The Lancet Infectious Diseases, 24:172-183, Feb 2024. URL: https://doi.org/10.1016/s1473-3099(23)00430-9, doi:10.1016/s1473-3099(23)00430-9. This article has 56 citations and is from a highest quality peer-reviewed journal.
(blankson2024understandingthepathogenesis pages 80-83): SO Blankson. Understanding the pathogenesis of severe malaria: the role of serological markers and plasma-derived extracellular vesicles. Unknown journal, 2024.
(blankson2024understandingthepathogenesisa pages 80-83): SO Blankson. Understanding the pathogenesis of severe malaria: the role of serological markers and plasma-derived extracellular vesicles. Unknown journal, 2024.
(gopinadhan2024ahumanpluripotent pages 8-10): Adnan Gopinadhan, Jason M. Hughes, Andrea L. Conroy, Chandy C. John, Scott G. Canfield, and Dibyadyuti Datta. A human pluripotent stem cell-derived in vitro model of the blood–brain barrier in cerebral malaria. Fluids and Barriers of the CNS, May 2024. URL: https://doi.org/10.1186/s12987-024-00541-9, doi:10.1186/s12987-024-00541-9. This article has 12 citations and is from a peer-reviewed journal.
(blankson2024understandingthepathogenesis pages 78-80): SO Blankson. Understanding the pathogenesis of severe malaria: the role of serological markers and plasma-derived extracellular vesicles. Unknown journal, 2024.
(wassmer2024unravellingmysteriesat pages 12-14): Samuel C. Wassmer, Tania F. de Koning-Ward, Georges E.R. Grau, and Saparna Pai. Unravelling mysteries at the perivascular space: a new rationale for cerebral malaria pathogenesis. Trends in Parasitology, 40:28-44, Jan 2024. URL: https://doi.org/10.1016/j.pt.2023.11.005, doi:10.1016/j.pt.2023.11.005. This article has 22 citations and is from a domain leading peer-reviewed journal.
(gopinadhan2024ahumanpluripotent media b2e9c3aa): Adnan Gopinadhan, Jason M. Hughes, Andrea L. Conroy, Chandy C. John, Scott G. Canfield, and Dibyadyuti Datta. A human pluripotent stem cell-derived in vitro model of the blood–brain barrier in cerebral malaria. Fluids and Barriers of the CNS, May 2024. URL: https://doi.org/10.1186/s12987-024-00541-9, doi:10.1186/s12987-024-00541-9. This article has 12 citations and is from a peer-reviewed journal.
(ekregbesi2024developingaphysiologic pages 13-16): POA Ekregbesi. Developing a physiologic model of placental malaria in mice. Unknown journal, 2024.
(blankson2024understandingthepathogenesis pages 220-224): SO Blankson. Understanding the pathogenesis of severe malaria: the role of serological markers and plasma-derived extracellular vesicles. Unknown journal, 2024.
(blankson2024understandingthepathogenesisa pages 220-224): SO Blankson. Understanding the pathogenesis of severe malaria: the role of serological markers and plasma-derived extracellular vesicles. Unknown journal, 2024.
(brito2024operationaleffectivenessof pages 1-3): Marcelo Brito, Rosilene Rufatto, José Diego Brito-Sousa, Felipe Murta, Vanderson Sampaio, Patrícia Balieiro, Djane Baía-Silva, Vanessa Castro, Brenda Alves, Aline Alencar, Stephan Duparc, Penny Grewal Daumerie, Isabelle Borghini-Fuhrer, Elodie Jambert, Cássio Peterka, Francisco Edilson Lima, Leonardo Carvalho Maia, Catherine Lucena Cruz, Bruna Maciele, Mariana Vasconcelos, Myrna Machado, Elder Augusto Figueira, Antônio Alcirley Balieiro, Dhelio Batista Pereira, and Marcus Lacerda. Operational effectiveness of tafenoquine and primaquine for the prevention of plasmodium vivax recurrence in brazil: a retrospective observational study. The Lancet Infectious Diseases, 24:629-638, Jun 2024. URL: https://doi.org/10.1016/s1473-3099(24)00074-4, doi:10.1016/s1473-3099(24)00074-4. This article has 28 citations and is from a highest quality peer-reviewed journal.
(musa2024impactandacceptability pages 1-2): Abuhuraira Ado Musa, Shuaibu Sulieman, Abdulbaqi Alhaji Magaji, Rashidat Oluwabukola Owolabi, and Maryam Dahiru Umar. Impact and acceptability of seasonal malaria chemoprevention (smc) and pharmacovigilance campaign among under-five children in nigeria: an explanatory study. Journal of Applied Health Sciences and Medicine, Jan 2024. URL: https://doi.org/10.58614/jahsm481, doi:10.58614/jahsm481. This article has 1 citations.
(shin20242023worldmalaria pages 1-4): Hyun-Il Shin, Bor-Ming Ku, Haneul Jung, So-dam Lee, Seon-Young Lee, Jung-Won Ju, Jonghee Kim, and Hee-Il Lee. 2023 world malaria report (status of world malaria in 2022). Public Health Weekly Report, 17:1351-1377, Jun 2024. URL: https://doi.org/10.56786/phwr.2024.17.32.1, doi:10.56786/phwr.2024.17.32.1. This article has 19 citations.
(dev2024editorialworldmalaria pages 1-2): Vas Dev and Kinley Wangdi. Editorial: world malaria day 2023 - ending malaria transmission: reaching the last mile to zero malaria. Frontiers in Public Health, Jun 2024. URL: https://doi.org/10.3389/fpubh.2024.1433213, doi:10.3389/fpubh.2024.1433213. This article has 2 citations.

{ }

Source YAML

click to show

name: Malaria
creation_date: "2026-02-20T00:00:00Z"
updated_date: "2026-02-20T16:02:29Z"
description: >-
  Malaria is a mosquito-borne protozoal infection caused by Plasmodium species,
  with major global burden from Plasmodium falciparum and Plasmodium vivax.
  Clinical disease is driven by blood-stage parasitemia, while severe falciparum
  syndromes involve microvascular sequestration and organ dysfunction, and vivax
  disease is complicated by relapse from dormant liver hypnozoites.
category: Infectious
disease_term:
  preferred_term: malaria
  term:
    id: MONDO:0005136
    label: malaria
parents:
- protozoal infectious disease
- vector-borne disease
synonyms:
- Paludism
- Marsh fever
has_subtypes:
- name: Plasmodium falciparum malaria
  subtype_term:
    preferred_term: Plasmodium falciparum malaria
    term:
      id: MONDO:0005920
      label: Plasmodium falciparum malaria
  description: Malaria caused by Plasmodium falciparum with highest risk of severe disease and cerebral complications.
  evidence:
  - reference: PMID:37924827
    reference_title: "Malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plasmodium falciparum strains partly resistant to artemisinins are entrenched in the Greater Mekong region and have emerged in Africa, while Anopheles mosquito vectors continue to evolve physiological and behavioural resistance to insecticides."
    explanation: Confirms falciparum malaria as a major clinical subtype with distinct resistance and transmission pressures.
- name: Plasmodium vivax malaria
  subtype_term:
    preferred_term: Plasmodium vivax malaria
    term:
      id: MONDO:0005921
      label: Plasmodium vivax malaria
  description: Malaria caused by Plasmodium vivax, notable for relapse biology driven by dormant liver hypnozoites.
  evidence:
  - reference: PMID:37748496
    reference_title: "Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear."
    explanation: Establishes P. vivax as a subtype with hypnozoite biology requiring radical cure.
- name: Cerebral malaria
  subtype_term:
    preferred_term: cerebral malaria
    term:
      id: MONDO:0005625
      label: cerebral malaria
  description: Severe neurologic malaria syndrome characterized by brain microvascular pathology, coma, and seizures.
  evidence:
  - reference: DOI:10.1186/s12987-024-00541-9
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Blood–brain barrier (BBB) disruption is a central feature of cerebral malaria (CM), a severe complication of Plasmodium falciparum (Pf) infections."
    explanation: Supports cerebral malaria as a distinct severe subtype with BBB-focused pathogenesis.
- name: Recurrent vivax malaria
  subtype_term:
    preferred_term: Plasmodium vivax malaria
    term:
      id: MONDO:0005921
      label: Plasmodium vivax malaria
  description: Recurrent disease episodes due to relapse from persistent liver hypnozoites after initial infection.
  evidence:
  - reference: PMID:37748496
    reference_title: "Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At day 180, the risk of recurrence was 51·0% (95% CI 48·2-53·9) in 1470 patients treated without primaquine, 19·3% (16·9-21·9) in 2569 patients treated with a low total dose of primaquine (approximately 3·5 mg/kg), and 8·1% (7·0-9·4) in 2811 patients treated with a high total dose of primaquine (approximately 7 mg/kg), regardless of primaquine treatment duration."
    explanation: Demonstrates substantial recurrence burden in vivax malaria and links recurrence to hypnozoite-targeted therapy.
infectious_agent:
- name: Plasmodium falciparum
  infectious_agent_term:
    preferred_term: Plasmodium falciparum
    term:
      id: NCBITaxon:5833
      label: Plasmodium falciparum
  description: The dominant species causing severe malaria syndromes, including cerebral malaria.
  evidence:
  - reference: DOI:10.1186/s12987-024-00541-9
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Blood–brain barrier (BBB) disruption is a central feature of cerebral malaria (CM), a severe complication of Plasmodium falciparum (Pf) infections."
    explanation: Identifies P. falciparum as a major causative agent linked to severe pathophysiology.
- name: Plasmodium vivax
  infectious_agent_term:
    preferred_term: Plasmodium vivax
    term:
      id: NCBITaxon:5855
      label: Plasmodium vivax
  description: A major malaria species characterized by hypnozoite-mediated relapse requiring radical cure.
  evidence:
  - reference: PMID:37748496
    reference_title: "Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear."
    explanation: Confirms P. vivax pathobiology and therapeutic implications.
agent_life_cycle:
  description: >-
    Infection proceeds from mosquito inoculation to liver-stage infection and
    blood-stage replication; P. vivax additionally persists as dormant
    hypnozoites that drive relapse.
  hosts:
  - preferred_term: Homo sapiens
    role: mammalian host for liver and blood stages
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  - preferred_term: Anopheles gambiae
    role: vector host for parasite transmission
    term:
      id: NCBITaxon:7165
      label: Anopheles gambiae
  vectors:
  - Female Anopheles mosquitoes
  life_cycle_stages:
  - name: Mosquito inoculation and hepatic invasion
    description: Sporozoites are inoculated by infected mosquitoes and establish liver infection.
    evidence:
    - reference: PMID:35921449
      reference_title: "Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "participants underwent controlled human malaria infection in which they were exposed to mosquitoes carrying Plasmodium falciparum (3D7 strain)."
      explanation: Human challenge model directly confirms mosquito-mediated inoculation as the initiating stage.
  - name: Erythrocytic blood-stage replication
    description: Asexual blood-stage replication drives the major symptomatic and severe manifestations of malaria.
    evidence:
    - reference: PMID:37924827
      reference_title: "Malaria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Parasitological diagnosis and treatment with oral or parenteral artemisinin-based therapy is the mainstay of patient management."
      explanation: Clinical mainstay centered on parasitological blood-stage diagnosis and treatment supports blood-stage disease biology.
  - name: Hypnozoite latency and relapse (P. vivax)
    description: Dormant liver-stage hypnozoites reactivate and cause recurrent vivax malaria.
    evidence:
    - reference: PMID:37748496
      reference_title: "Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear."
      explanation: Supports dormant liver-stage biology underlying relapse in vivax malaria.
transmission:
- name: Mosquito-borne transmission
  description: Transmission occurs through the bite of infected female Anopheles mosquitoes.
  evidence:
  - reference: PMID:35921449
    reference_title: "Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "participants underwent controlled human malaria infection in which they were exposed to mosquitoes carrying Plasmodium falciparum (3D7 strain)."
    explanation: Human challenge data directly supports mosquito-borne transmission.
  - reference: PMID:37924827
    reference_title: "Malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Plasmodium falciparum strains partly resistant to artemisinins are entrenched in the Greater Mekong region and have emerged in Africa, while Anopheles mosquito vectors continue to evolve physiological and behavioural resistance to insecticides."
    explanation: Identifies Anopheles mosquitoes as epidemiologically central vectors.
epidemiology:
- name: Global burden in 2022
  description: Malaria remains a high-burden disease with hundreds of millions of cases and substantial mortality.
  evidence:
  - reference: DOI:10.58614/jahsm481
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Globally, an estimated 249 million malaria cases occurred in 2022, leading to 608,000 malaria deaths in a single year."
    explanation: Provides explicit contemporary burden estimates.
  - reference: PMID:40056919
    reference_title: "Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum and Plasmodium vivax malaria, 2000-22: a spatial and temporal modelling study."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Malaria remains a leading cause of illness and death globally, with countries in sub-Saharan Africa bearing a disproportionate burden."
    explanation: Computational burden mapping supports persistent high global and regional burden.
- name: Stalled incidence progress in sub-Saharan Africa
  description: Gains in incidence reduction have plateaued in many high-burden settings since 2015.
  evidence:
  - reference: PMID:40056919
    reference_title: "Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum and Plasmodium vivax malaria, 2000-22: a spatial and temporal modelling study."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "We found an ongoing plateau in rates of malaria infection prevalence and case incidence within sub-Saharan Africa, with consistent year-on-year improvements not evident since 2015."
    explanation: Directly supports recent stagnation in incidence reduction.
progression:
- phase: Hepatic stage
  duration: Approximately days to weeks after inoculation
  notes: Clinically silent liver-stage replication precedes blood-stage disease.
  evidence:
  - reference: PMID:35921449
    reference_title: "Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "participants underwent controlled human malaria infection in which they were exposed to mosquitoes carrying Plasmodium falciparum (3D7 strain)."
    explanation: Human challenge model establishes the early post-inoculation phase that precedes parasitemia.
- phase: Blood stage
  duration: Acute symptomatic period
  notes: Blood-stage parasitemia drives febrile illness and organ complications.
  evidence:
  - reference: PMID:37924827
    reference_title: "Malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Parasitological diagnosis and treatment with oral or parenteral artemisinin-based therapy is the mainstay of patient management."
    explanation: Clinical management centered on blood-stage parasitemia supports this progression phase.
- phase: Relapse phase (vivax malaria)
  duration: Recurrent episodes through follow-up windows up to 180 days
  notes: Recurrence in vivax malaria is driven by persistent hypnozoites.
  evidence:
  - reference: PMID:37748496
    reference_title: "Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At day 180, the risk of recurrence was 51·0% (95% CI 48·2-53·9) in 1470 patients treated without primaquine, 19·3% (16·9-21·9) in 2569 patients treated with a low total dose of primaquine (approximately 3·5 mg/kg), and 8·1% (7·0-9·4) in 2811 patients treated with a high total dose of primaquine (approximately 7 mg/kg), regardless of primaquine treatment duration."
    explanation: Quantifies recurrent vivax episodes over time and response to hypnozoite-active therapy.
pathophysiology:
- name: Infected erythrocyte sequestration and cytoadherence
  description: >-
    In severe falciparum malaria, parasitized erythrocytes sequester in the
    microvasculature, promoting endothelial injury, impaired perfusion, and
    downstream organ dysfunction.
  cell_types:
  - preferred_term: erythrocyte
    term:
      id: CL:0000232
      label: erythrocyte
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: cell adhesion
    term:
      id: GO:0007155
      label: cell adhesion
  locations:
  - preferred_term: blood
    term:
      id: UBERON:0000178
      label: blood
  downstream:
  - target: Blood-brain barrier dysfunction in cerebral malaria
    description: Microvascular sequestration contributes to BBB injury and neurologic manifestations.
  evidence:
  - reference: PMID:27939609
    reference_title: "EPCR and Malaria Severity: The Center of a Perfect Storm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infected erythrocyte sequestration in the microvasculature plays a critical role in the development of severe disease"
    explanation: Directly supports sequestration as a central severe-malaria mechanism.
- name: Blood-brain barrier dysfunction in cerebral malaria
  description: >-
    Cerebral malaria involves endothelial barrier breakdown with increased
    permeability and stress responses, linking vascular pathology to severe
    neurologic phenotypes.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Coma
    description: Barrier dysfunction and microvascular pathology contribute to cerebral edema and coma.
  - target: Seizure
    description: Cerebral vascular and inflammatory injury contributes to seizure risk.
  evidence:
  - reference: DOI:10.1186/s12987-024-00541-9
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Blood–brain barrier (BBB) disruption is a central feature of cerebral malaria (CM), a severe complication of Plasmodium falciparum (Pf) infections."
    explanation: Establishes BBB disruption as a core pathophysiologic feature of cerebral malaria.
  - reference: DOI:10.1186/s12987-024-00541-9
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "After 6-h of co-culture with Pf-iRBCs, hiPSC-BMECs showed reduced TEER and increased sodium fluorescein permeability compared to co-culture with uninfected RBCs, indicative of a leaky barrier."
    explanation: Demonstrates mechanistic endothelial barrier failure in an in vitro CM model.
- name: EPCR-associated endothelial pathology
  description: >-
    Parasite interactions with endothelial protein C receptor (EPCR) are
    associated with severe disease and suggest a pathway for enhanced vascular
    injury and dysregulated coagulation-inflammatory signaling.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:27939609
    reference_title: "EPCR and Malaria Severity: The Center of a Perfect Storm."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The recent discovery that parasite binding to endothelial protein C receptor (EPCR) is associated with severe disease has suggested new mechanisms of pathology and provided new avenues for severe malaria adjunctive therapy research."
    explanation: Supports EPCR-linked endothelial pathology as a severity mechanism.
- name: Cerebrovascular CD8-positive T-cell engagement
  description: >-
    Pediatric cerebral malaria includes intravascular and perivascular CD8-positive
    T-cell engagement at the cerebrovasculature, supporting an immune-mediated
    component of neurologic injury.
  cell_types:
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:31821175
    reference_title: "CD8+ T cells target cerebrovasculature in children with cerebral malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified effector CD3+CD8+ T cells engaged on the cerebrovasculature in 69% of CM+ HIV- children."
    explanation: Provides direct human tissue evidence for cerebrovascular CD8-positive T-cell involvement.
  - reference: PMID:31821175
    reference_title: "CD8+ T cells target cerebrovasculature in children with cerebral malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Within the studied cohort, CM is associated with cerebrovascular engagement of CD3+CD8+ T cells, which is exacerbated by HIV coinfection."
    explanation: Confirms association between cerebral malaria and cerebrovascular CD8-positive T-cell activity.
- name: ABO-dependent rosetting and severe malaria risk
  description: >-
    Host ABO genotype modifies falciparum rosetting behavior and contributes to
    differential risk of severe malaria.
  cell_types:
  - preferred_term: erythrocyte
    term:
      id: CL:0000232
      label: erythrocyte
  biological_processes:
  - preferred_term: cell adhesion
    term:
      id: GO:0007155
      label: cell adhesion
  locations:
  - preferred_term: blood
    term:
      id: UBERON:0000178
      label: blood
  evidence:
  - reference: PMID:37708213
    reference_title: "Non-O ABO blood group genotypes differ in their associations with Plasmodium falciparum rosetting and severe malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blood group O is associated with protection against severe malaria and reduced size and stability of P. falciparum-host red blood cell (RBC) rosettes compared to non-O blood groups."
    explanation: Supports RBC rosetting and host blood-group dependence in severe malaria risk.
  - reference: PMID:37708213
    reference_title: "Non-O ABO blood group genotypes differ in their associations with Plasmodium falciparum rosetting and severe malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the case-control study, compared to OO, the double dose genotypes consistently had higher odds ratios (OR) for severe malaria than single dose genotypes, with AB (OR 1.93) and AO (OR 1.27) showing most marked difference (p = 0.02, Wald test)."
    explanation: Restricts this evidence item to human case-control findings on genotype-specific severe-malaria risk.
- name: Hypnozoite persistence and vivax relapse
  description: >-
    Dormant P. vivax hypnozoites in the liver sustain recurrent malaria episodes
    unless eradicated with radical cure.
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Recurrent vivax malaria
    description: Persistence of hypnozoites drives repeated blood-stage episodes.
  evidence:
  - reference: PMID:37748496
    reference_title: "Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear."
    explanation: Directly links dormant hypnozoites to the need for radical cure in recurrent vivax malaria.
phenotypes:
- name: Fever
  description: >-
    Fever is the dominant presenting symptom of acute clinical malaria.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:8644955
    reference_title: "Emergency department presentation and misdiagnosis of imported falciparum malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common documented symptoms were fever (100%), chills (65%), vomiting (60%), anorexia (45%), and headache (45%)."
    explanation: Clinical case-series data show fever as the most frequent presenting feature.
- name: Chills
  description: Chills and rigors are common constitutional manifestations in acute malaria.
  phenotype_term:
    preferred_term: Chills
    term:
      id: HP:0025143
      label: Chills
  frequency: FREQUENT
  evidence:
  - reference: PMID:8644955
    reference_title: "Emergency department presentation and misdiagnosis of imported falciparum malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common documented symptoms were fever (100%), chills (65%), vomiting (60%), anorexia (45%), and headache (45%)."
    explanation: Clinical series directly reports chills as a frequent presenting symptom.
- name: Headache
  description: Headache is a frequent constitutional symptom in symptomatic malaria.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  frequency: FREQUENT
  evidence:
  - reference: PMID:8644955
    reference_title: "Emergency department presentation and misdiagnosis of imported falciparum malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common documented symptoms were fever (100%), chills (65%), vomiting (60%), anorexia (45%), and headache (45%)."
    explanation: Reported headache prevalence supports inclusion as a common malaria phenotype.
- name: Vomiting
  description: Gastrointestinal symptoms including vomiting are common in acute malaria presentations.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  frequency: FREQUENT
  evidence:
  - reference: PMID:8644955
    reference_title: "Emergency department presentation and misdiagnosis of imported falciparum malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common documented symptoms were fever (100%), chills (65%), vomiting (60%), anorexia (45%), and headache (45%)."
    explanation: Case-series symptom profile supports vomiting as a frequent manifestation.
- name: Myalgia
  description: Muscle pain is a frequent systemic symptom in uncomplicated malaria.
  phenotype_term:
    preferred_term: Myalgia
    term:
      id: HP:0003326
      label: Myalgia
  frequency: FREQUENT
  evidence:
  - reference: PMID:17568940
    reference_title: "Clinical spectrum of uncomplicated malaria in semi-immune Amazonians: beyond the \" symptomatic \" vs \" asymptomatic \" dichotomy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Headache (59.8%), fever (57.1%), and myalgia (48.4%) were the most frequent symptoms."
    explanation: Prospective cohort data identifies myalgia among the most frequent malaria symptoms.
- name: Anemia
  description: Malaria can cause clinically significant anemia, especially in severe disease.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  frequency: FREQUENT
  evidence:
  - reference: PMID:8644955
    reference_title: "Emergency department presentation and misdiagnosis of imported falciparum malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There were no deaths, and complications were limited to thrombocytopenia and anemia."
    explanation: Clinical complications in falciparum malaria include anemia.
- name: Thrombocytopenia
  description: Platelet depletion is a common hematologic complication of malaria.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  frequency: FREQUENT
  evidence:
  - reference: PMID:8644955
    reference_title: "Emergency department presentation and misdiagnosis of imported falciparum malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There were no deaths, and complications were limited to thrombocytopenia and anemia."
    explanation: Directly supports thrombocytopenia as a clinical complication.
- name: Splenomegaly
  description: Splenic enlargement is a recognized manifestation in malaria, particularly with vivax-predominant presentations.
  subtype: Plasmodium vivax malaria
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:25889074
    reference_title: "Clinical profile of Plasmodium falciparum and Plasmodium vivax infections in low and unstable malaria transmission settings of Colombia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fever, tachycardia, pallor and abdominal pain on palpation were more frequent in P. falciparum patients, whereas mild hepatomegaly and splenomegaly were mostly observed with P. vivax."
    explanation: Large Colombian clinical surveillance cohort documents splenomegaly, especially in vivax infection.
- name: Coma
  description: Cerebral malaria can present with coma as a defining severe neurologic manifestation.
  subtype: Cerebral malaria
  severity: Severe
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  frequency: OCCASIONAL
  diagnostic: true
  evidence:
  - reference: PMID:40701686
    reference_title: "Cerebral malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease is defined clinically as an otherwise unexplained coma in someone with malaria parasitemia."
    explanation: Human clinical neurology review defines coma as the core phenotype of cerebral malaria.
- name: Seizure
  description: Seizures are a major severe neurologic manifestation in cerebral malaria.
  subtype: Cerebral malaria
  severity: Severe
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  frequency: OCCASIONAL
  diagnostic: true
  evidence:
  - reference: PMID:40701686
    reference_title: "Cerebral malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acute seizures are common and increasing numbers of them during the index illness are associated with a greater likelihood of adverse outcomes."
    explanation: Human clinical evidence supports seizures as common, prognostically relevant cerebral-malaria manifestations.
genetic:
- name: HBB (HbS trait)
  association: Protective
  notes: Sickle cell trait (HbAS) is one of the strongest known host genetic protective modifiers against severe falciparum malaria.
  evidence:
  - reference: PMID:22445352
    reference_title: "Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Meta-analysis of case-control studies showed a decreased risk of severe P. falciparum malaria in individuals with haemoglobin AS (OR 0·09, 95% CI 0·06-0·12), haemoglobin CC (0·27, 0·11-0·63), haemoglobin AC (0·83, 0·67-0·96), homozygous α-thalassaemia (0·63, 0·48-0·83), and heterozygous α-thalassaemia (0·83, 0·74-0·92)."
    explanation: Meta-analysis provides strong human clinical evidence for marked severe-malaria protection in HbAS.
  - reference: PMID:23035141
    reference_title: "Sickle cell trait protects against Plasmodium falciparum infection."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although sickle cell trait protects against severe disease due to Plasmodium falciparum, it has not been clear whether sickle trait also protects against asymptomatic infection (parasitemia)."
    explanation: Confirms HbAS as a major protective modifier in falciparum malaria.
- name: G6PD
  association: Protective modifier and pharmacogenomic risk factor
  notes: G6PD deficiency can reduce severe-malaria risk in specific genotypes while increasing risk of drug-induced hemolysis with primaquine.
  evidence:
  - reference: PMID:17355169
    reference_title: "X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results indicate that the uniform state of G6PD deficiency in hemizygous male children conferred significant protection against severe, life-threatening malaria, and that it may have likewise protected homozygous female children."
    explanation: Case-control evidence supports genotype-specific protection from severe malaria.
  - reference: PMID:24372186
    reference_title: "G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is now clear that it is not good practice to give one of these drugs before testing a person for his/her G6PD status, especially in populations in whom G6PD deficiency is common."
    explanation: Supports clinically important pharmacogenomic implications for primaquine safety.
- name: ACKR1 (Duffy antigen receptor for chemokines)
  association: Strong protective modifier for Plasmodium vivax
  notes: The FY*O (Duffy-null) background is a major vivax resistance factor, but Duffy-independent vivax infection can still occur.
  evidence:
  - reference: PMID:30218021
    reference_title: "Susceptibility to Plasmodium vivax malaria associated with DARC (Duffy antigen) polymorphisms is influenced by the time of exposure to malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The variants of the Duffy Antigen/Receptor for Chemokines (DARC) gene have probably been selected by malaria parasites, particularly the FY*O allele, which is fixed in sub-Saharan Africa and confers resistance to Plasmodium vivax infection."
    explanation: Human population genetics evidence supports Duffy-null resistance against vivax malaria.
  - reference: PMID:37399221
    reference_title: "Potential hidden Plasmodium vivax malaria reservoirs from low parasitemia Duffy-negative Ethiopians: Molecular evidence."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "This study confirms that Duffy-negativity does not provide complete protection against P. vivax infection."
    explanation: Adds modern nuance that protection is strong but not absolute in all endemic contexts.
- name: HBB (HbC)
  association: Protective
  notes: HbC is associated with reduced severe falciparum malaria risk, with stronger protection in homozygotes.
  evidence:
  - reference: PMID:15295709
    reference_title: "Hemoglobin C and resistance to severe malaria in Ghanaian children."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HbAC did not prevent infection but reduced the odds of developing severe malaria and severe anemia."
    explanation: Case-control data supports protection from severe outcomes despite ongoing infection risk.
- name: HBA1/HBA2 (alpha-thalassemia)
  association: Protective
  notes: Both heterozygous and homozygous alpha-thalassemia reduce severe-malaria risk.
  evidence:
  - reference: PMID:22445352
    reference_title: "Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Meta-analysis of case-control studies showed a decreased risk of severe P. falciparum malaria in individuals with haemoglobin AS (OR 0·09, 95% CI 0·06-0·12), haemoglobin CC (0·27, 0·11-0·63), haemoglobin AC (0·83, 0·67-0·96), homozygous α-thalassaemia (0·63, 0·48-0·83), and heterozygous α-thalassaemia (0·83, 0·74-0·92)."
    explanation: Meta-analysis shows significant protective effects for alpha-thalassemia genotypes.
- name: HBB (beta-thalassemia trait)
  association: Protective (lower parasitemia)
  notes: Beta-thalassemia trait is associated with lower parasitemia, though evidence is less extensive than for HbAS, HbC, and alpha-thalassemia.
  evidence:
  - reference: PMID:8846492
    reference_title: "Genetic red cell disorders and severity of falciparum malaria in Myanmar."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean parasitaemia levels of patients with alpha- or beta-thalassaemia trait or with severe glucose-6-phosphate dehydrogenase (G6PD) deficiency were lower than those of individuals with normal haemoglobin AA or with heterozygous haemoglobin E."
    explanation: Human observational data supports reduced parasitemia in beta-thalassemia trait.
  - reference: PMID:22445352
    reference_title: "Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Few clinical studies have investigated β-thalassaemia, haemoglobin E, P. vivax malaria, or pregnancy-associated malaria."
    explanation: Indicates supporting literature is more limited than for other major malaria-protective polymorphisms.
- name: ABO
  association: Susceptibility
  notes: Non-O genotypes are associated with increased falciparum rosetting and elevated severe-malaria risk.
  evidence:
  - reference: PMID:37708213
    reference_title: "Non-O ABO blood group genotypes differ in their associations with Plasmodium falciparum rosetting and severe malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the case-control study, compared to OO, the double dose genotypes consistently had higher odds ratios (OR) for severe malaria than single dose genotypes, with AB (OR 1.93) and AO (OR 1.27) showing most marked difference (p = 0.02, Wald test)."
    explanation: Human case-control data support increased severe-malaria risk in double-dose non-O genotypes.
diagnosis:
- name: Parasitological diagnosis
  description: Diagnosis is based on direct parasitological confirmation of malaria infection.
  evidence:
  - reference: PMID:37924827
    reference_title: "Malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Parasitological diagnosis and treatment with oral or parenteral artemisinin-based therapy is the mainstay of patient management."
    explanation: Supports parasitological confirmation as core diagnostic practice.
- name: Rapid diagnostic test-based case ascertainment
  description: Rapid diagnostic tests are used in field and clinical settings to define clinical malaria with fever.
  evidence:
  - reference: PMID:40991921
    reference_title: "Permethrin-Treated Baby Wraps for the Prevention of Malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary outcome was clinical malaria in the children, as defined by fever and a positive malaria rapid diagnostic test."
    explanation: Supports RDT-based clinical case definition.
differential_diagnoses:
- name: Dengue disease
  description: Mosquito-borne viral febrile illness that frequently overlaps clinically with malaria in tropical settings.
  distinguishing_features:
  - Prominent retro-orbital pain, rash, and severe myalgia are more typical of dengue.
  - Plasma leakage and hemoconcentration with severe thrombocytopenia support severe dengue.
  - Dengue NS1 antigen or serology supports dengue over malaria when blood film/RDT for malaria is negative.
  disease_term:
    preferred_term: dengue disease
    term:
      id: MONDO:0005502
      label: dengue disease
  evidence:
  - reference: PMID:27759344
    reference_title: "Expanded Dengue."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Moreover it is a great mimic of co-existing epidemics like Malaria, Chikungunya and Zika virus disease, which are also mosquito-borne diseases."
    explanation: Review explicitly identifies dengue as a clinical mimic of malaria in co-endemic settings.
- name: chikungunya
  description: Arboviral febrile illness that can be confused with malaria, especially during outbreaks.
  distinguishing_features:
  - Severe incapacitating polyarthralgia with prolonged joint symptoms is more characteristic of chikungunya.
  - Maculopapular rash is common and cyclic parasitemia is absent.
  - Chikungunya PCR/serology with negative malaria parasitology supports chikungunya.
  disease_term:
    preferred_term: chikungunya
    term:
      id: MONDO:0017941
      label: chikungunya
  evidence:
  - reference: PMID:27759344
    reference_title: "Expanded Dengue."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Moreover it is a great mimic of co-existing epidemics like Malaria, Chikungunya and Zika virus disease, which are also mosquito-borne diseases."
    explanation: Supports chikungunya as an overlapping mosquito-borne differential diagnosis for malaria.
- name: typhoid fever
  description: Invasive Salmonella infection causing prolonged fever that can resemble uncomplicated malaria.
  distinguishing_features:
  - Sustained stepwise fever pattern with abdominal symptoms and enteric features.
  - Positive blood culture for Salmonella Typhi supports typhoid fever.
  - Lack of malaria parasitemia on repeated testing argues against malaria.
  disease_term:
    preferred_term: typhoid fever
    term:
      id: MONDO:0005619
      label: typhoid fever
  evidence:
  - reference: PMID:26261776
    reference_title: "Severe scrub typhus infection: Clinical features, diagnostic challenges and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Since the symptoms and signs are non-specific and resemble other tropical infections like malaria, enteric fever, dengue or leptospirosis, appropriate laboratory tests are necessary to confirm diagnosis."
    explanation: Directly identifies enteric fever (typhoid) as a key tropical differential when evaluating malaria-like febrile illness.
- name: leptospirosis
  description: Zoonotic bacterial febrile illness with multiorgan involvement that can mimic severe malaria.
  distinguishing_features:
  - Exposure to contaminated water or animal urine supports leptospirosis risk.
  - Conjunctival suffusion, jaundice, and acute kidney injury are suggestive in severe cases.
  - Positive leptospira serology/PCR with negative malaria parasitology supports leptospirosis.
  disease_term:
    preferred_term: leptospirosis
    term:
      id: MONDO:0005825
      label: leptospirosis
  evidence:
  - reference: PMID:26261776
    reference_title: "Severe scrub typhus infection: Clinical features, diagnostic challenges and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Since the symptoms and signs are non-specific and resemble other tropical infections like malaria, enteric fever, dengue or leptospirosis, appropriate laboratory tests are necessary to confirm diagnosis."
    explanation: Supports leptospirosis as a common mimic requiring targeted testing in malaria-like presentations.
datasets:
- accession: geo:GSE1124
  title: Whole blood transcriptome of childhood malaria
  description: >-
    Whole-blood microarray profiling across asymptomatic infection,
    uncomplicated malaria, severe malarial anemia, cerebral malaria, and
    healthy controls in African children.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_types:
  - preferred_term: whole blood
    tissue_term:
      preferred_term: blood
      term:
        id: UBERON:0000178
        label: blood
  sample_count: 47
  conditions:
  - asymptomatic Plasmodium falciparum infection
  - uncomplicated malaria
  - severe malarial anemia
  - cerebral malaria
  - healthy controls
  platform: Affymetrix Human Genome U133A and U133B Arrays
  publication: PMID:30638864
  notes: GEO series metadata reports pooled whole-blood expression profiling across pediatric malaria severity strata.
- accession: geo:GSE116306
  title: Blood transcriptional profiles discriminates cerebral and mild malaria patient living in Senegal
  description: >-
    PBMC microarray profiling comparing mild and cerebral malaria at clinical
    presentation in Senegalese participants.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_types:
  - preferred_term: peripheral blood mononuclear cell
    tissue_term:
      preferred_term: blood
      term:
        id: UBERON:0000178
        label: blood
  sample_count: 16
  conditions:
  - mild malaria
  - cerebral malaria
  platform: Agilent SurePrint G3 Human GE 8x60K Microarray
  notes: GEO series metadata indicates no linked PubMed citation currently recorded in GEO.
- accession: geo:GSE117613
  title: Whole-blood transcriptional signatures composed of erythropoietic and Nrf2-regulated genes differ between cerebral malaria and severe malarial anemia
  description: >-
    Whole-blood transcriptome microarray study in Ugandan children comparing
    cerebral malaria, severe malarial anemia, and community controls without
    P. falciparum infection.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_types:
  - preferred_term: whole blood
    tissue_term:
      preferred_term: blood
      term:
        id: UBERON:0000178
        label: blood
  sample_count: 46
  conditions:
  - cerebral malaria
  - severe malarial anemia
  - community control without Plasmodium falciparum infection
  platform: Illumina HumanHT-12 v4 Expression BeadChip
  publication: PMID:30060095
  notes: Captures host whole-blood transcriptional differences between major severe-malaria syndromes.
treatments:
- name: Artemisinin-based antimalarial therapy
  description: Oral or parenteral artemisinin-based therapy remains the treatment mainstay for malaria.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:37924827
    reference_title: "Malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Parasitological diagnosis and treatment with oral or parenteral artemisinin-based therapy is the mainstay of patient management."
    explanation: Directly supports frontline antimalarial pharmacotherapy.
- name: Primaquine radical cure for vivax malaria
  description: Primaquine reduces recurrent vivax malaria by targeting dormant liver hypnozoites.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  target_mechanisms:
  - target: Hypnozoite persistence and vivax relapse
    treatment_effect: INHIBITS
    description: Primaquine targets dormant hypnozoites to reduce recurrent episodes.
    evidence:
    - reference: PMID:37748496
      reference_title: "Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Increasing the total dose of primaquine from 3·5 mg/kg to 7 mg/kg can reduce P vivax recurrences by more than 50% in most endemic regions"
      explanation: Supports mechanism-linked reduction in relapse burden.
  evidence:
  - reference: PMID:37748496
    reference_title: "Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compared with treatment without primaquine, the rate of P vivax recurrence was lower after treatment with low-dose primaquine (adjusted hazard ratio 0·21, 95% CI 0·17-0·27; p<0·0001) and high-dose primaquine (0·10, 0·08-0·12; p<0·0001)."
    explanation: Demonstrates major recurrence-risk reduction with primaquine.
- name: Supportive care in severe malaria
  description: Severe malaria management includes organ support and restrictive fluid strategy to improve survival.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:37924827
    reference_title: "Malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Timely blood transfusion, renal replacement therapy, and restrictive fluid therapy can improve survival in severe malaria."
    explanation: Supports critical-care supportive interventions in severe disease.
- name: Insecticide-treated bed nets
  description: Insecticide-treated bed nets are a core vector-control intervention that reduces malaria burden by limiting mosquito exposure.
  treatment_term:
    preferred_term: medical action
    term:
      id: MAXO:0000001
      label: medical action
  evidence:
  - reference: PMID:22445352
    reference_title: "Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including intermittent preventive antimalarial therapy in children (87% to 69%)74,75 or infants (38%)76 and the use of insecticide-treated bed nets (45%).77"
    explanation: Human epidemiologic synthesis identifies insecticide-treated bed nets as a major malaria-control intervention.
- name: Intermittent preventive treatment and seasonal chemoprevention
  description: Drug-based preventive strategies such as IPTp and seasonal chemoprevention reduce malaria morbidity in high-risk populations.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:37924827
    reference_title: "Malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rigorous use of intermittent preventive treatment in pregnancy and infancy and seasonal chemoprevention, potentially combined with pre-erythrocytic vaccines endorsed by WHO in 2021 and 2023, can substantially reduce malaria morbidity."
    explanation: Directly supports IPTp/infancy preventive treatment and seasonal chemoprevention as morbidity-reducing strategies.
- name: Pre-erythrocytic malaria vaccination (RTS,S and R21)
  description: WHO-endorsed pre-erythrocytic vaccines are deployed to reduce clinical malaria burden in endemic pediatric populations.
  treatment_term:
    preferred_term: vaccination
    term:
      id: MAXO:0001017
      label: vaccination
  evidence:
  - reference: PMID:37924827
    reference_title: "Malaria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rigorous use of intermittent preventive treatment in pregnancy and infancy and seasonal chemoprevention, potentially combined with pre-erythrocytic vaccines endorsed by WHO in 2021 and 2023, can substantially reduce malaria morbidity."
    explanation: Supports clinical deployment of RTS,S (2021) and R21 (2023) era malaria vaccines as morbidity-reduction interventions.
clinical_trials:
- name: NCT04704830
  phase: PHASE_III
  status: UNKNOWN
  description: Phase III multicenter trial evaluating efficacy of R21/Matrix-M in African children.
  target_phenotypes:
  - preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: clinicaltrials:NCT04704830
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria"
    explanation: Trial registry evidence for phase III vaccine efficacy evaluation in malaria.
- name: NCT04158713
  phase: PHASE_III
  status: UNKNOWN
  description: Placebo-controlled chemoprevention trial of monthly dihydroartemisinin-piperaquine in HIV-infected pregnant participants on cotrimoxazole.
  target_phenotypes:
  - preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  - preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: clinicaltrials:NCT04158713
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is a 2-arm, individually-randomized, multi-centre, placebo-controlled superiority trial comparing the safety and efficacy of daily CTX plus monthly DP ('CTX-DP') versus daily CTX plus monthly placebo-DP (i.e. 'CTX-alone', control arm) to reduce malaria and the adverse effects of malaria in 898 (449 per arm) HIV-infected pregnant women on DTG-based cARTs."
    explanation: Registry record supports active clinical testing of preventive pharmacotherapy in a high-risk population.
- name: NCT05019729
  phase: PHASE_I
  status: UNKNOWN
  description: Phase I controlled human malaria infection study evaluating safety and protective efficacy of anti-malaria monoclonal antibody L9LS.
  target_phenotypes:
  - preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: clinicaltrials:NCT05019729
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most participants took part in the controlled human malaria infection (CHMI) or malaria challenge to find out if L9LS prevents malaria after being bitten by infected mosquitos."
    explanation: Registry evidence supports early-phase interventional prevention trial design.